Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F21%3AE0109141" target="_blank" >RIV/00843989:_____/21:E0109141 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/21:00075847 RIV/00064165:_____/21:10429479

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.26282" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/ajh.26282</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ajh.26282" target="_blank" >10.1002/ajh.26282</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

Popis výsledku v původním jazyce

The assessment of patient-reported outcomes (PROs) has become an important component in clinical trials as they provide information on the impact of a disease and treatment from the patient's perspective. The BOSTON trial is the first study of a bortezomib-based triplet therapy that showed lower rates of overall and Grade ? 2 PN compared with doublet Vd while conferring a longer PFS and fewer clinic visits than standard twice weekly Vd. As the survival of patients with MM are improving, the need to minimize cumulative side effects such as PN becomes more important to improve QoL. The reduction in PN-related pain and sensory symptoms observed with XVd in this setting of increased PFS, time to next therapy, and patient-preferred oral administration supports a potentially improved patient experience and decreased health care burden and long-term morbidity.

Název v anglickém jazyce

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

Popis výsledku anglicky

The assessment of patient-reported outcomes (PROs) has become an important component in clinical trials as they provide information on the impact of a disease and treatment from the patient's perspective. The BOSTON trial is the first study of a bortezomib-based triplet therapy that showed lower rates of overall and Grade ? 2 PN compared with doublet Vd while conferring a longer PFS and fewer clinic visits than standard twice weekly Vd. As the survival of patients with MM are improving, the need to minimize cumulative side effects such as PN becomes more important to improve QoL. The reduction in PN-related pain and sensory symptoms observed with XVd in this setting of increased PFS, time to next therapy, and patient-preferred oral administration supports a potentially improved patient experience and decreased health care burden and long-term morbidity.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American journal of hematology

ISSN

0361-8609

e-ISSN

1096-8652

Svazek periodika

96

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

1

Strana od-do

e383-e386

Kód UT WoS článku

000671882800001

EID výsledku v databázi Scopus

2-s2.0-85109791260